Burnishing its rare disease drug ambitions, Sanofi picks up fast FDA OK for Cablivi — courtesy of a $4.8B buyout
Following up on last fall’s European approval for caplacizumab as a new treatment for a rare blood disease, Sanofi today followed up with the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
